



Xigduo® XR (dapagliflozin/metformin) – First-time authorized brand alternative

- On January 3, 2024, [Prasco launched](#) an authorized brand alternative of AstraZeneca's [Xigduo XR \(dapagliflozin/metformin\)](#) extended-release tablets.
- Xigduo XR is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Xigduo XR carries a boxed warning for lactic acidosis.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.